The global marine pharmaceuticals market size is calculated at USD 6.52 billion in 2025 and is expected to reach around USD 10.34 billion by 2034, growing at a CAGR of 5.29% for the forecasted period.
Ottawa, Nov. 19, 2025 (GLOBE NEWSWIRE) — The global marine pharmaceuticals market size was valued at USD 6.19 billion in 2024 and is predicted to hit around USD 10.34 billion by 2034, rising at a 5.29% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research. The marine pharmaceuticals market growth is driven by unique marine biodiversity, advances in marine bioprospecting and synthetic biology, and growing R&D investment.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/6308
Key Takeaways
- North America held a major share of approximately 40% of the marine pharmaceuticals market in 2024.
- Asia Pacific is expected to witness the fastest CAGR during 2025-2034.
- By source, the marine microorganisms segment held a major share of approximately 35% of the market in 2024.
- By source, the macroalgae/seaweeds segment is expected to witness the fastest CAGR during 2025-2034.
- By compound type, the peptides & peptidomimetics segment held a major share of approximately 30% of the market in 2024.
- By compound type, the polysaccharides & glycoconjugates segment is expected to witness the fastest CAGR during 2025-2034.
- By therapeutic application, the oncology/anticancer segment held a major share of approximately 30-35% of the marine pharmaceuticals market in 2024.
- By therapeutic application, the anti-infective segment is expected to witness the fastest CAGR during 2025-2034.
- By product type, the active pharmaceutical ingredients (APIs) segment held a major share of approximately 40% of the market in 2024.
- By product type, the semi-synthetic/synthetic derivatives segment is expected to witness the fastest CAGR during 2025-2034..
Market Overview & Potential
What Is The Growth Potential Responsible For The Growth Of The Marine Pharmaceuticals Market?
The marine pharmaceuticals market is driven by the increasing prevalence of chronic diseases, the demand for natural and novel therapies, and advancements in biotechnology and research. These factors fuel the discovery and development of new drugs from marine organisms to treat conditions like cancer, Alzheimer’s, and infectious diseases. Increased investment in research and development, along with government support, further propels this growth.
Key Indicators and Highlights
| Table | Scope | |
| Market Size in 2025 | USD 6.52 Billion | |
| Projected Market Size in 2034 | USD 10.34 Billion | |
| CAGR (2025 – 2034) | 5.29 | % |
| Leading Region | North America by 40% | |
| Market Segmentation | By Source, By Compound Type, By Therapeutic Application, By Product Type, By Region | |
| Top Key Players | PharmaMar S.A., Nereus Pharmaceuticals, Sirenas (Sirenas Marine Discovery/Sirenas LLC), GlycoMar Ltd, Marinomed Biotech AG, Aker BioMarine, Cyanotech Corporation, Marinova Ptd Ltd., SeaPharm, Inc., Biomar Microbial Technologies, Martek Biosciences / DSM, InnovaSea , Abyss Ingr | |
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
What Are the Trends Associated with the Marine Pharmaceuticals Market?
Drug discovery from marine biodiversity: Marine life is a vast source of novel compounds with therapeutic potential, making bioprospecting a central driver for the market.
Focus on oncology and infectious diseases: A major application area is the development of anti-cancer drugs, antibiotics, and anti-inflammatory agents. The rise of antibiotic-resistant bacteria is also creating a new need for novel antimicrobials.
Increased R&D and collaboration: Companies are boosting research and development efforts and forming strategic partnerships to streamline compound discovery and accelerate pipeline development.
Technological advancements: New technologies are improving the efficiency of research and the synthesis of marine-derived compounds.
What Is the Growing Challenge in the Marine Pharmaceuticals Market?
Marine pharmaceuticals face major challenges, including complex drug development, which leads to a high failure rate for candidates. Other key hurdles include sustainable and cost-effective supply of compounds, environmental and ecological concerns from harvesting, and complex regulatory pathways for marine-derived drugs.
Regional Analysis
How Did North America Dominate the Marine Pharmaceuticals Market in 2024?
North America held a major share of approximately 40% of the marine pharmaceuticals market in 2024. The North American marine pharmaceuticals market is the largest in the world, driven by the high prevalence of chronic diseases like cancer and Alzheimer’s, and significant government and private investment in research and development. Key factors fueling growth include government support from agencies like NOAA and NIH, increasing awareness of marine-derived drug potential, and the diverse marine life along the coasts. The market is projected to continue its upward trend due to the ongoing search for new marine-based therapeutics and advancements in compound discovery.
What Made the Asia Pacific Significantly Grow in The Marine Pharmaceuticals Market In 2024?
Asia Pacific is expected to witness the fastest CAGR during 2025-2034. The Asia-Pacific marine pharmaceuticals market is projected to be the fastest-growing region globally, driven by the region’s rich marine biodiversity, increasing investment in marine research and biotechnology, and government support. China, Japan, and South Korea are leading the market, fueled by expanded research pipelines and collaborations with academic and international pharmaceutical firms. Key growth drivers include rising healthcare demand, government funding, and advancements in technology like AI.
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
Segmental Insights
By source,
The marine microorganisms segment held a major share of approximately 35% of the market in 2024. Marine microorganisms, including bacteria, fungi, and actinomycetes, are major contributors to marine-derived drug discovery due to their ability to produce highly novel metabolites. These organisms offer structurally diverse compounds with potent bioactivities, making them especially valuable for anticancer, anti-infective, and anti-inflammatory drug development pipelines.
The macroalgae/seaweeds segment is expected to witness the fastest CAGR during 2025-2034. Macroalgae and seaweeds serve as rich sources of bioactive polysaccharides, peptides, and secondary metabolites with therapeutic potential. Their high abundance, sustainability, and biocompatibility support their growing use in developing antiviral, antioxidant, and immunomodulatory pharmaceutical candidates, particularly for chronic disease management.
By compound type,
The peptides & peptidomimetics segment held a major share of approximately 30% of the market in 2024. Marine-derived peptides and peptidomimetics exhibit strong antimicrobial, anticancer, and anti-inflammatory properties due to unique amino acid sequences and marine-specific structural modifications. These compounds are increasingly used in targeted therapies, benefiting from high specificity, lower toxicity, and compatibility with modern drug delivery systems.
The polysaccharides & glycoconjugates segment is expected to witness the fastest CAGR during 2025-2034. Marine polysaccharides and glycoconjugates, including fucoidan, alginate, and carrageenan, are valued for their antiviral, anticoagulant, and immunomodulatory effects. Their multifunctional biological activity, natural origin, and ease of extraction are driving significant interest in developing new therapeutics, nutraceuticals, and biomedical formulations.
Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership
By therapeutic application,
The oncology/anticancer segment held a major share of approximately 30-35% of the marine pharmaceuticals market in 2024. Marine-derived compounds are widely researched for oncology due to their novel mechanisms of action, cytotoxicity toward tumour cells, and ability to overcome drug resistance. Several marine-origin anticancer drugs and candidates target signalling pathways, angiogenesis, and apoptosis, making this one of the fastest-growing application segments.
The anti-infective segment is expected to witness the fastest CAGR during 2025-2034. Marine anti-infective compounds offer strong activity against antibiotic-resistant bacteria, viruses, and fungi. Their structural novelty and potent antimicrobial mechanisms support the development of next-generation anti-infective drugs, especially amid rising antimicrobial resistance and limited success of terrestrial-derived compounds.
By product type,
The active pharmaceutical ingredients (APIs) segment held a major share of approximately 40% of the market in 2024. Marine-derived APIs form the backbone of commercialised marine pharmaceuticals, providing high-value molecules for oncology, pain management, and infectious disease therapies. These APIs originate from microorganisms, algae, and invertebrates, and undergo extensive purification and characterisation before integration into drug formulations.
The semi-synthetic/synthetic derivatives segment is expected to witness the fastest CAGR during 2025-2034. Semi-synthetic and synthetic derivatives enhance the stability, potency, and pharmacokinetic properties of natural marine compounds. By modifying marine scaffolds, researchers can optimise therapeutic performance while improving scalability for industrial production, which is essential for commercialising marine drug candidates on a large scale.
Browse More Insights of Towards Healthcare:
The global pharmaceutical-grade melatonin market was valued at USD 479.9 million in 2024, rising to USD 521 million in 2025, and is projected to reach USD 1,044.3 million by 2034, expanding at a CAGR of 8.56% from 2025 to 2034.
The global pharmaceutical spray drying market stood at USD 2.37 billion in 2024, increased to USD 2.55 billion in 2025, and is expected to reach USD 4.93 billion by 2034, growing at a CAGR of 7.67% between 2025 and 2034.
The global pharmaceutical secondary packaging market was valued at USD 43.11 billion in 2024, increased to USD 45.24 billion in 2025, and is anticipated to reach USD 69.45 billion by 2034, registering a CAGR of 4.94% over the forecast period.
The global pharmaceutical filtration market is projected to grow from USD 14.95 billion in 2025 to USD 30.09 billion by 2034, expanding at a CAGR of 8.08% from 2025 to 2034.
The global pharmaceutical water market was valued at USD 38.70 billion in 2023 and is expected to reach USD 107.15 billion by 2034, advancing at a CAGR of 9.25% from 2024 to 2034.
The global pharmaceutical packaging market was valued at USD 139.40 billion in 2023 and is projected to surge to USD 387.50 billion by 2034, growing at a strong CAGR of 9.74% during 2024–2034.
The global pharmaceutical stability and storage services market was valued at USD 3.4 billion in 2024, grew to USD 3.59 billion in 2025, and is forecasted to reach USD 5.92 billion by 2034, expanding at a CAGR of 5.7% from 2025 to 2034.
The global pharmaceutical CDMO market was estimated at USD 146.05 billion in 2023 and is projected to reach USD 315.08 billion by 2034, at a CAGR of 7.24% from 2024 to 2034.
The global pharmaceutical logistics market was valued at USD 105.6 million in 2023 and is expected to grow to USD 191.1 million by 2034, expanding at a CAGR of 5.54% between 2024 and 2034.
The global pharmaceutical excipients market stood at USD 10.83 billion in 2025, increased to USD 11.27 billion in 2026, and is projected to reach USD 16.12 billion by 2035, growing at a CAGR of 4.06% from 2026 to 2035.
Recent Developments
- In August 2025, finding novel natural compounds from marine species is the goal of a recent joint research project between Chuo University and Nippon Yusen Kabushiki Kaisha (NYK). Surprisingly, this study uses marine organisms that stick to ship hulls and other surfaces to identify chemicals that have not yet been identified but could be beneficial to humanity, including potential new pharmaceutical resources, and to elucidate their effects.
- In August 2024, researchers from the Skaggs School of Pharmacy and Pharmaceutical Sciences and UC San Diego’s Scripps Institution of Oceanography created a new method for searching the oceans for unique substances that may one day be used to make medications and other products.
Marine Pharmaceuticals Market Key Players List
- PharmaMar S.A.
- Nereus Pharmaceuticals
- Sirenas (Sirenas Marine Discovery/Sirenas LLC)
- GlycoMar Ltd
- Marinomed Biotech AG
- Aker BioMarine
- Cyanotech Corporation
- Marinova Ptd Ltd.
- SeaPharm, Inc.
- Biomar Microbial Technologies
- Martek Biosciences / DSM
- InnovaSea
- Abyss Ingredients
- Salinomycin
- OncoMarine
- Kancor Ingredients
- Evotec
- Aquapharm
Segments Covered in The Report
By Source
- Marine Microorganisms (bacteria, cyanobacteria, fungi)
- Macroalgae/Seaweeds
- Marine Invertebrates (sponges, tunicates, molluscs, corals)
- Marine Vertebrates & Venoms (fish, cone snails, jellyfish)
- Others
By Compound Type
- Peptides & Peptidomimetics
- Alkaloids & Terpenoids
- Polysaccharides & Glycoconjugates
- Lipids & Fatty-acid Derivatives
- Small Molecules (non-peptidic)
- Others
By Therapeutic Application
- Oncology/Anticancer
- Anti-infective (Antibacterial, Antiviral, Antifungal)
- Anti-inflammatory & Immunomodulatory
- Neurological Disorders
- Metabolic & Cardiovascular Disorders
- Dermatology & Wound Care
- Others
By Product Type
- Active Pharmaceutical Ingredients (APIs) marine-derived
- Semi-synthetic / Synthetic Derivatives (marine-inspired)
- Formulated Drug Products (injectables, oral, topical)
- Nutraceuticals & Marine-derived Ingredients
- Research Reagents & Probes
By Region
- North America
- U.S.
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/6308
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web: https://www.towardshealthcare.com
Our Trusted Data Partners
Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.